REG - Morgan Stanley Cap - Rule 38.5 - ABBVIE INC.

Morgan StanleyAnnouncement

18/03/2020 11:50

RNS Number : 6221G
  
Morgan Stanley Capital Services LLC
  
18 March 2020
  
 

 
 FORM 38.5 
 
IRISH TAKEOVER PANEL
 
DISCLOSURE UNDER RULE 38.5 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER  RULES, 2007 (AS AMENDED)
 
DEALINGS BY CONNECTED EXEMPT MARKET-MAKERS
 
1.             KEY INFORMATION



 Name of exempt market-maker


   Morgan Stanley Capital Services LLC




 Company dealt in


   ABBVIE INC.




 Class of relevant security to which the dealings being disclosed relate (Note 1)


  US$0.01 COMMON STOCK




 Date of dealing


   17 MARCH 2020



 
 
2.             DEALINGS (Note 2)
 
(a)           Purchases and sales



 Total number of relevant secuities accquired


 Highest price paid (Note 3)


 Lowest price paid (Note 3)




  113,169


 79.1514 USD


 70.0000 USD



 



 Total number of relevant secuities disposed


 Highest price paid (Note 3)


 Lowest price paid (Note 3)




  115,131


 77.7727 USD


 70.0050 USD



 
 
(b)           Derivatives transactions (other than options transactions)
 



 Product name, e.g. CFD


 Nature of transaction 
                (Note 4)


 Number of relevant securities 
                (Note 5)


 Price per unit




 CFD


 LONG


 16,927


 70.2740 USD




 CFD


 LONG


 393


 70.2740 USD




 CFD


 LONG


 14,604


 71.9799 USD




 CFD


 LONG


 5,513


 72.2738 USD




 CFD


 LONG


 94


 73.0200 USD




 CFD


 LONG


 53


 73.0964 USD




 CFD


 LONG


 947


 73.0964 USD




 CFD


 LONG


 1,890


 73.1306 USD




 CFD


 LONG


 1,129


 73.3336 USD




 CFD


 LONG


 171


 73.3336 USD




 CFD


 LONG


 10,710


 73.7063 USD




 CFD


 LONG


 2,200


 74.4751 USD




 CFD


 LONG


 400


 74.4751 USD




 CFD


 LONG


 800


 74.4751 USD




 CFD


 LONG


 400


 74.4751 USD




 CFD


 LONG


 144


 74.5940 USD




 CFD


 LONG


 96


 74.6800 USD




 CFD


 LONG


 44


 74.8880 USD




 CFD


 LONG


 21,650


 74.9031 USD




 CFD


 LONG


 4,700


 75.6034 USD




 CFD


 LONG


 16,926


 75.7095 USD




 CFD


 LONG


 394


 75.7095 USD




 CFD


 LONG


 2,900


 76.2976 USD




 CFD


 SHORT


 12,000


 72.4116 USD




 CFD


 SHORT


 241


 72.5200 USD




 CFD


 SHORT


 2,933


 72.6420 USD




 CFD


 SHORT


 621


 73.0200 USD




 CFD


 SHORT


 7,777


 73.0200 USD




 CFD


 SHORT


 43,300


 74.2906 USD




 CFD


 SHORT


 18,186


 74.3622 USD




 CFD


 SHORT


 300


 74.5233 USD




 CFD


 SHORT


 2,858


 75.0149 USD




 CFD


 SHORT


 3,637


 75.9807 USD



 
 
(c)            Options transactions in respect of existing relevant securities
 
i)           Writing, selling, purchasing or varying
 



 Product name, eg call option


 Writing, selling, purchasing, varying etc


 Number of securities to which the option relates (Note 5)


 Exercise Price


 Type, e.g American, European etc 


 Expiry Date 


 Option money paid/received per unit (Note 3)




 N/A


 N/A


 N/A


 N/A


 N/A


 N/A


 N/A 



 
(ii) Exercising
 



 Product name, eg call option


 Number of securities


 Exercise price per unit (Note 3)




 N/A


 N/A


 N/A  



 
 
3. OTHER INFORMATION
 
Agreements, arrangements or understandings relating to options or derivatives
 



Full Details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.
 




 
 
 
 
 



 
 



 Date of disclosure


 18 MARCH 2020




 Contact Name


Craig Horsley




 Telephone Number


+44(141) 245 7736 




 Name of offeree/offeror with which connected


ABBVIE INC. 




Nature of connection (Note 6)


Advisory 



 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
  END
 
 
ISEUWSRRRNUOAAR